How the ESC 2020 Congress Went Virtual

Video

A look at how a major international cardiovascular meeting changed its structure in 4 months.

The European Society of Cardiology (ESC) 2020 Congress featured 4000-plus abstracts, 300-plus session topics, and nearly 40 industry sponsors.

And the entire international meeting is occurring online.

Like every prominent medical meeting planned for this year, ESC was forced to reform its agenda and offerings to a virtual format due to coronavirus 2019 (COVID-19). Unlike most other conferences, it did so with very little sacrifice of its frequently robust offering of sessions, posters, and networking opportunities.

In an interview with HCPLive during the virtual congress, ESC President Barbara Casadei, MD, DPhil, discussed the challenges that went into turning around a major cardiovascular meeting in 4 months.

“We’ve had more than 100,000 participants when the first ‘hotline’ session started yesterday,” Casadei said on Sunday. “We are extremely grateful for the people who were able to do that for us, but we were also extremely grateful that the whole system may crash."

Casadei explained the conventional, in-person congress was already fully planned when the society received word in April that the Dutch government would not permit it in full attendee size due to COVID-19. Early discussion was centered around whether to retain the full agenda, or condense it for the online meeting—the chose the former, with trepidation.

“My view was that if we take the congress as we have it, and we make it digital, it would be like translating Shakespeare with Google Translate,” she said. “It’s a completely different thing that needs to be re-thought.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.